Quidelortho's Cash & cash equivalent grew by 34.85 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Quidelortho's Quick Ratio to 0.16, Quick Ratio remained below Quidelortho Corp average.

Within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Quidelortho in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 3300 to 3676.

Explain Quick Ratio?
How much Cash & cash equivalents QDEL�s has?
What are QDEL�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

QDEL Quick Ratio	(Sep 27 2026) Q3	(Jun 28 2026) Q2	(Mar 29 2026) Q1	(Dec 28 2025) Q4	(Sep 28 2025) Q3
Y / Y Current Liabilities Change	38.96 %	-13.02 %	-8.1 %	-1.04 %	-25.25 %
Y / Y Cash & cash equivalent Change	69.62 %	-18.66 %	10.46 %	72.74 %	-31.73 %
Quick Ratio MRQ	0.16	0.12	0.15	0.17	0.13
QDEL's Total Ranking	# 3676	# 3300	# 2617	# 3000	#
Seq. Current Liabilities Change	7.42 %	3.22 %	-3.02 %	29.24 %	-32.76 %
Seq. Cash & cash equivalent Change	34.85 %	-12.11 %	-17.31 %	73.09 %	-35.33 %

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 847
Overall Market	# 3676

Quick Ratio Statistics
High	Average	Low
6.86	1.81	0.1
(Jun 30 2016)		(Dec 29 2024)

Financial Statements
Quidelortho's Current Liabilities	$ 1,067 Millions	Visit QDEL's Balance sheet
Quidelortho's Cash & cash equivalent	$ 166 Millions	Visit QDEL's Balance sheet
Source of QDEL's Sales		Visit QDEL's Sales by Geography

Cumulative Quidelortho's Quick Ratio

QDEL's Quick Ratio for the trailling 12 Months

QDEL Quick Ratio	(Sep 27 2026) 12 Months	(Jun 28 2026) 12 Months	(Mar 29 2026) 12 Months	(Dec 28 2025) 12 Months	(Sep 28 2025) 12 Months
Y / Y Current Liabilities TTM Growth	1.4 %	-11.93 %	-3.61 %	5.54 %	9.16 %
Y / Y Cash & cash equivalent TTM Growth	26.26 %	2.09 %	17.62 %	27.88 %	-4.29 %
Quick Ratio TTM	0.15	0.14	0.14	0.14	0.12
Total Ranking TTM	# 4107	# 3976	# 3157	# 3086	#
Seq. Current Liabilities TTM Growth	8.05 %	-3.85 %	-2.15 %	-0.26 %	-6.15 %
Seq. Cash & cash equivalent TTM Growth	12.85 %	-5.05 %	2.43 %	15.05 %	-8.76 %

Quick ratio ranking by company, industry and sector >> Back to QDEL Financial Strength Comparisons >> Go to Compare QDEL Quick Ratio to its Competitors

On the trailing twelve months basis QDEL Cash & cash equivalent soared by 69.62 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Quidelortho's Quick Ratio to 0.15, Quick Ratio remained below QDEL average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Quidelortho. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3976 to 4107.

Explain Quick Ratio?
How much Cash & cash equivalents QDEL�s has?
What are QDEL�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 909
Within the Market	# 4107

trailing twelve months Quick Ratio Statistics
High	Average	Low
6.08	1.84	0.11
(Sep 30 2016)		(Dec 29 2024)

Companies with similar Quick Ratio in the quarter ending Sep 27 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Sep 27 2026 MRQ Cash & cash equivalent	Sep 27 2026 MRQ Current Liabilities
Neogen Corporation	0.19	$ 172.000 Millions	$ 899.100 Millions
Idexx Laboratories Inc	0.16	$ 197.536 Millions	$ 1,264.222 Millions
Quidelortho Corp	0.16	$ 166.400 Millions	$ 1,067.100 Millions

Date modified: 2026-11-06T13:06:08+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.